Abstract
Successful cancer immunotherapy requires novel approaches that overcome intratumoral immunosuppression and peripheral tolerance. In a recent manuscript describing intravenously administered mRNA-loaded lipid particle aggregates (RNA-LPAs), we demonstrate the ability to reprogram both the tumor microenvironment and periphery enabling cancer-specific immunity simultaneously generated to compete against immunologically 'cold' malignancies like glioblastoma.